In our center, a total of 451 peritoneal dialysis catheters were implanted in 424 uremic patients from 1986 to 1999. All catheters were implanted by the percutaneous method of Di Paolo. From 1986 to May 1997 (period A), we inserted 389 catheters using the Weston-Roberts catheter armed with a metallic sharp mandrel for the first access to the peritoneal cavity. After May 1997 (period B), we implanted 62 peritoneal dialysis catheters, replacing the metallic sharp mandrel with the Veress needle to arm the Weston-Roberts catheter. The aim of this retrospective study was to determine the incidence of early complications (within 2 weeks) and to compare the incidence between the two groups (period A versus period B). The results suggest that the incidence of perforation of abdominal organs is lower, but not significantly so, when the Veress needle is used.

Download full-text PDF

Source

Publication Analysis

Top Keywords

peritoneal dialysis
12
veress needle
12
percutaneous method
8
dialysis catheters
8
catheters implanted
8
1997 period
8
weston-roberts catheter
8
metallic sharp
8
sharp mandrel
8
placement peritoneal
4

Similar Publications

Background: Fulminant myocarditis (FM) is a potentially lethal disease with a wide spectrum of clinical presentation, thus making the diagnosis hard to depict. In cases where acute circulatory failure occurs venoarterial (VA) extracorporeal membrane oxygenation (ECMO) support is a valid management strategy, especially in the pediatric and adult patients. This study aims to report the results of VA ECMO for FM in our Institution.

View Article and Find Full Text PDF

Rationale & Objective: Nearly half of kidney transplant recipients develop allograft failure within 10 years of transplantation and experience high mortality, significant symptom burden, and complex communication challenges. These patients may benefit from palliative care, but palliative care is infrequently provided in this population. This study explores palliative care perceptions and needs among patients with poorly functioning and declining kidney allografts.

View Article and Find Full Text PDF

Background: Few studies have evaluated the predictive capability of equations for residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD). Moreover, the applicability of each equation remains unclear. Therefore, we aimed to evaluate the performances of the estimated RKF (eRKF) equations of Shafi, Steubl, and Jaques in Chinese patients undergoing continuous ambulatory peritoneal dialysis (CAPD).

View Article and Find Full Text PDF

Differences in dialysis modality choice between immigrant and native populations in Barcelona, Spain.

Nefrologia (Engl Ed)

January 2025

Servicio de Nefrología, Hospital del Mar, Instituto Hospital del Mar de Investigaciones Médicas, RD16/0009/0013 (ISCIII FEDER REDinREN), Barcelona, Spain; Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain.

Few studies have analyzed the freedom to choose their renal replacement treatment (RRT) modality in Spain. In a total of 673 patients with ACKD (stage 4 and 5) seen at the outpatient ACKD clinic of Hospital del Mar, Barcelona, Catalonia (Spain) from 2009 to 2020, we retrospectively compared immigrant and Spanish patients in order to analyze the impact of migration on RRT decision-making and its subsequent evolution in advanced CKD (ACKD) consultation and identifies the social and economic needs of this population. One hundred thirteen (16.

View Article and Find Full Text PDF

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.

Nephrol Dial Transplant

November 2024

Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).

Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!